 Cara Wilson
Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 34 | 2024 | 839 | 4.720 |
Why?
| | HIV Infections | 47 | 2024 | 2729 | 4.330 |
Why?
| | Intestinal Mucosa | 11 | 2021 | 593 | 3.660 |
Why?
| | CD4-Positive T-Lymphocytes | 22 | 2022 | 1058 | 3.460 |
Why?
| | Gastrointestinal Microbiome | 11 | 2024 | 641 | 2.370 |
Why?
| | Dysbiosis | 8 | 2022 | 170 | 2.280 |
Why?
| | Immunity, Mucosal | 5 | 2017 | 94 | 1.840 |
Why?
| | Dendritic Cells | 12 | 2020 | 481 | 1.800 |
Why?
| | Lymphocyte Activation | 13 | 2017 | 1109 | 1.540 |
Why?
| | Bacterial Translocation | 6 | 2019 | 40 | 1.460 |
Why?
| | Interferon-gamma | 10 | 2019 | 773 | 1.420 |
Why?
| | Colon | 5 | 2024 | 257 | 1.400 |
Why?
| | Gastrointestinal Tract | 5 | 2022 | 186 | 1.320 |
Why?
| | Lymphocytes | 3 | 2021 | 377 | 1.310 |
Why?
| | Epitopes, T-Lymphocyte | 8 | 2010 | 186 | 1.230 |
Why?
| | Butyrates | 2 | 2021 | 56 | 1.210 |
Why?
| | Viremia | 6 | 2016 | 132 | 1.190 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 174 | 1.030 |
Why?
| | Immunity, Innate | 4 | 2021 | 804 | 1.020 |
Why?
| | Escherichia coli | 3 | 2014 | 766 | 0.970 |
Why?
| | AIDS Vaccines | 5 | 2016 | 47 | 0.930 |
Why?
| | Th1 Cells | 2 | 2019 | 137 | 0.900 |
Why?
| | Granzymes | 2 | 2022 | 47 | 0.900 |
Why?
| | Bacteria | 4 | 2022 | 812 | 0.830 |
Why?
| | Viral Load | 11 | 2016 | 449 | 0.810 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 108 | 0.770 |
Why?
| | Interleukin-23 | 2 | 2013 | 19 | 0.760 |
Why?
| | Ruminococcus | 1 | 2021 | 9 | 0.730 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.730 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2008 | 170 | 0.710 |
Why?
| | Interleukin-15 | 1 | 2021 | 83 | 0.700 |
Why?
| | Microbiota | 5 | 2023 | 734 | 0.690 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 208 | 0.640 |
Why?
| | HIV Core Protein p24 | 5 | 2006 | 31 | 0.640 |
Why?
| | Vaccines, DNA | 3 | 2016 | 28 | 0.630 |
Why?
| | Immunologic Factors | 2 | 2018 | 229 | 0.620 |
Why?
| | Pyrrolidinones | 3 | 2014 | 29 | 0.610 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 44 | 0.610 |
Why?
| | Th17 Cells | 1 | 2019 | 85 | 0.610 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 69 | 0.610 |
Why?
| | T-Lymphocytes | 8 | 2021 | 1935 | 0.600 |
Why?
| | Inflammation | 9 | 2021 | 2741 | 0.560 |
Why?
| | Gene Products, gag | 5 | 2007 | 36 | 0.560 |
Why?
| | Interferon Type I | 1 | 2018 | 139 | 0.550 |
Why?
| | Interleukins | 1 | 2019 | 241 | 0.550 |
Why?
| | Aging | 2 | 2020 | 1770 | 0.540 |
Why?
| | Receptors, IgG | 2 | 2014 | 73 | 0.530 |
Why?
| | Ritonavir | 2 | 2013 | 73 | 0.480 |
Why?
| | Humans | 65 | 2024 | 129527 | 0.480 |
Why?
| | Anti-HIV Agents | 5 | 2014 | 757 | 0.460 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 39 | 0.440 |
Why?
| | HIV Antigens | 3 | 2016 | 17 | 0.440 |
Why?
| | Adult | 30 | 2024 | 35505 | 0.440 |
Why?
| | Flow Cytometry | 7 | 2017 | 1158 | 0.430 |
Why?
| | Cells, Cultured | 9 | 2021 | 4087 | 0.430 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 84 | 0.430 |
Why?
| | Apoptosis | 2 | 2014 | 2488 | 0.420 |
Why?
| | Young Adult | 17 | 2020 | 12438 | 0.410 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2014 | 267 | 0.410 |
Why?
| | Middle Aged | 28 | 2024 | 31087 | 0.400 |
Why?
| | Virus Replication | 5 | 2016 | 453 | 0.390 |
Why?
| | Interferon-alpha | 3 | 2020 | 194 | 0.390 |
Why?
| | Sulfonamides | 2 | 2013 | 497 | 0.380 |
Why?
| | Movement | 1 | 2014 | 266 | 0.380 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 426 | 0.370 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2016 | 855 | 0.370 |
Why?
| | Immunophenotyping | 6 | 2014 | 310 | 0.360 |
Why?
| | Monocytes | 1 | 2013 | 554 | 0.340 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 6 | 0.340 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 38 | 0.330 |
Why?
| | Caspase 3 | 1 | 2010 | 244 | 0.320 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 232 | 0.320 |
Why?
| | Interleukin-2 | 4 | 2022 | 437 | 0.320 |
Why?
| | Myeloid Cells | 1 | 2010 | 141 | 0.320 |
Why?
| | RNA, Viral | 5 | 2014 | 620 | 0.310 |
Why?
| | CD4 Lymphocyte Count | 6 | 2014 | 267 | 0.300 |
Why?
| | Cytokines | 8 | 2018 | 2018 | 0.300 |
Why?
| | Interleukin-17 | 3 | 2023 | 110 | 0.300 |
Why?
| | Male | 28 | 2024 | 63586 | 0.290 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 67 | 0.290 |
Why?
| | Cross-Sectional Studies | 5 | 2018 | 5078 | 0.280 |
Why?
| | Antiviral Agents | 3 | 2020 | 719 | 0.280 |
Why?
| | Phenotype | 5 | 2019 | 3058 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 4 | 2024 | 546 | 0.270 |
Why?
| | Cell Proliferation | 7 | 2021 | 2367 | 0.260 |
Why?
| | Conserved Sequence | 2 | 2003 | 227 | 0.250 |
Why?
| | CD57 Antigens | 1 | 2005 | 16 | 0.250 |
Why?
| | Interleukin-10 | 2 | 2021 | 298 | 0.250 |
Why?
| | Case-Control Studies | 9 | 2022 | 3383 | 0.240 |
Why?
| | GPI-Linked Proteins | 3 | 2016 | 67 | 0.240 |
Why?
| | Female | 23 | 2024 | 68650 | 0.230 |
Why?
| | Lipopolysaccharide Receptors | 3 | 2021 | 85 | 0.230 |
Why?
| | Biomarkers | 7 | 2021 | 3968 | 0.220 |
Why?
| | Aged | 12 | 2021 | 22063 | 0.220 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 41 | 0.220 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 34 | 0.210 |
Why?
| | Viral Proteins | 1 | 2006 | 327 | 0.210 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2021 | 707 | 0.210 |
Why?
| | Chloroquine | 2 | 2016 | 51 | 0.200 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 19 | 0.200 |
Why?
| | Arthritis, Experimental | 1 | 2023 | 135 | 0.190 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1684 | 0.190 |
Why?
| | Yeasts | 1 | 2002 | 52 | 0.190 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 530 | 0.190 |
Why?
| | Blood | 1 | 2022 | 105 | 0.180 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 125 | 0.180 |
Why?
| | Propionates | 1 | 2021 | 38 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 228 | 0.180 |
Why?
| | Immunoglobulin A | 1 | 2022 | 201 | 0.180 |
Why?
| | Acetates | 1 | 2021 | 100 | 0.170 |
Why?
| | Acetylation | 1 | 2021 | 243 | 0.170 |
Why?
| | Interferons | 1 | 2022 | 189 | 0.170 |
Why?
| | Genetic Vectors | 1 | 2002 | 309 | 0.170 |
Why?
| | Interferon-beta | 1 | 2020 | 89 | 0.170 |
Why?
| | Bacteria, Anaerobic | 1 | 2020 | 22 | 0.170 |
Why?
| | Immunity, Humoral | 2 | 2022 | 118 | 0.160 |
Why?
| | Immunologic Memory | 3 | 2009 | 349 | 0.160 |
Why?
| | Adaptive Immunity | 1 | 2021 | 161 | 0.160 |
Why?
| | Immune Tolerance | 2 | 2014 | 356 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 206 | 0.160 |
Why?
| | Shoulder | 1 | 2020 | 86 | 0.160 |
Why?
| | Receptors, Cell Surface | 1 | 2021 | 381 | 0.160 |
Why?
| | Raltegravir Potassium | 3 | 2014 | 17 | 0.150 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2019 | 84 | 0.150 |
Why?
| | Phylogeny | 2 | 2017 | 843 | 0.150 |
Why?
| | Lymphocyte Depletion | 2 | 2012 | 134 | 0.150 |
Why?
| | Diet, High-Fat | 1 | 2019 | 239 | 0.150 |
Why?
| | Transcriptome | 2 | 2022 | 875 | 0.150 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2006 | 51 | 0.140 |
Why?
| | Microbial Interactions | 1 | 2017 | 16 | 0.140 |
Why?
| | Antigens, CD | 4 | 2016 | 485 | 0.140 |
Why?
| | Proteome | 1 | 2022 | 440 | 0.140 |
Why?
| | Feces | 2 | 2019 | 442 | 0.140 |
Why?
| | Cell Differentiation | 3 | 2011 | 1895 | 0.130 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 82 | 0.130 |
Why?
| | Interleukin-1beta | 1 | 2019 | 368 | 0.130 |
Why?
| | Chronic Disease | 5 | 2010 | 1722 | 0.130 |
Why?
| | Fungi | 1 | 2017 | 136 | 0.130 |
Why?
| | Darunavir | 2 | 2013 | 18 | 0.130 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 231 | 0.130 |
Why?
| | Histones | 1 | 2021 | 589 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2017 | 323 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 483 | 0.120 |
Why?
| | Interleukin-12 | 1 | 2016 | 118 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 3150 | 0.120 |
Why?
| | Colitis | 1 | 2017 | 245 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1098 | 0.120 |
Why?
| | Rifamycins | 1 | 2014 | 5 | 0.120 |
Why?
| | In Vitro Techniques | 2 | 2014 | 1091 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1087 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 524 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 3 | 2007 | 412 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2016 | 265 | 0.110 |
Why?
| | HLA-DR Antigens | 3 | 2008 | 223 | 0.110 |
Why?
| | Polyamines | 1 | 2014 | 39 | 0.110 |
Why?
| | Thromboplastin | 1 | 2014 | 70 | 0.110 |
Why?
| | CD56 Antigen | 1 | 2014 | 36 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7052 | 0.110 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 776 | 0.110 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2055 | 0.110 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 117 | 0.110 |
Why?
| | Physical Fitness | 1 | 2015 | 202 | 0.110 |
Why?
| | Intestines | 1 | 2017 | 350 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 190 | 0.100 |
Why?
| | Caspase 1 | 1 | 2014 | 142 | 0.100 |
Why?
| | Mucous Membrane | 1 | 2014 | 125 | 0.100 |
Why?
| | Adolescent | 6 | 2019 | 20409 | 0.100 |
Why?
| | Homeostasis | 1 | 2017 | 605 | 0.100 |
Why?
| | Melanoma | 2 | 2011 | 728 | 0.100 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 157 | 0.100 |
Why?
| | Pilot Projects | 1 | 2017 | 1594 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 239 | 0.100 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 349 | 0.100 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.090 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2827 | 0.090 |
Why?
| | HIV Seropositivity | 2 | 2019 | 120 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 264 | 0.090 |
Why?
| | Antibodies, Viral | 1 | 2015 | 602 | 0.090 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 21 | 0.090 |
Why?
| | Cell Survival | 1 | 2014 | 1084 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2544 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 486 | 0.090 |
Why?
| | Motor Activity | 1 | 2015 | 686 | 0.090 |
Why?
| | Antigens, CD1 | 1 | 2010 | 58 | 0.080 |
Why?
| | Disease Progression | 3 | 2019 | 2628 | 0.080 |
Why?
| | Exercise | 1 | 2021 | 1931 | 0.080 |
Why?
| | Cytomegalovirus | 2 | 2015 | 154 | 0.080 |
Why?
| | Signal Transduction | 2 | 2021 | 4916 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 315 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2016 | 1873 | 0.070 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.070 |
Why?
| | Sequence Alignment | 2 | 2006 | 330 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 338 | 0.070 |
Why?
| | HLA-A3 Antigen | 2 | 2004 | 6 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2016 | 2135 | 0.070 |
Why?
| | HLA-A2 Antigen | 2 | 2004 | 48 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 507 | 0.070 |
Why?
| | Fluorides | 1 | 2006 | 50 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 182 | 0.070 |
Why?
| | Polyurethanes | 1 | 2006 | 38 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 50 | 0.060 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 11 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 477 | 0.060 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 249 | 0.060 |
Why?
| | Methacrylates | 1 | 2006 | 113 | 0.060 |
Why?
| | HIV | 1 | 2007 | 227 | 0.060 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 28 | 0.060 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 45 | 0.060 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 82 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 836 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 372 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 187 | 0.060 |
Why?
| | Antigenic Variation | 1 | 2004 | 10 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1708 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2138 | 0.060 |
Why?
| | Beryllium | 1 | 2005 | 152 | 0.060 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.050 |
Why?
| | Retroelements | 1 | 2024 | 44 | 0.050 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2024 | 30 | 0.050 |
Why?
| | Superantigens | 1 | 2003 | 70 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 121 | 0.050 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 139 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 185 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2724 | 0.050 |
Why?
| | Animals | 6 | 2023 | 35334 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 215 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 171 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 3702 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 57 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 83 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 262 | 0.050 |
Why?
| | HLA-DRB1 Chains | 1 | 2003 | 108 | 0.050 |
Why?
| | Tryptophan | 1 | 2023 | 177 | 0.050 |
Why?
| | Epitopes | 1 | 2004 | 473 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 787 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2003 | 135 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 88 | 0.050 |
Why?
| | Mice | 4 | 2023 | 16973 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2022 | 109 | 0.050 |
Why?
| | Collagen | 1 | 2023 | 436 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 363 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 336 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 86 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 936 | 0.040 |
Why?
| | Lipopolysaccharides | 2 | 2014 | 872 | 0.040 |
Why?
| | Alleles | 1 | 2003 | 843 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 57 | 0.040 |
Why?
| | Cohort Studies | 2 | 2010 | 5423 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1950 | 0.040 |
Why?
| | Metagenome | 1 | 2019 | 140 | 0.040 |
Why?
| | Inpatients | 1 | 2022 | 476 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 156 | 0.030 |
Why?
| | Body Composition | 1 | 2021 | 649 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 724 | 0.030 |
Why?
| | Symbiosis | 1 | 2017 | 71 | 0.030 |
Why?
| | Protein Binding | 1 | 2003 | 2121 | 0.030 |
Why?
| | APOBEC-3G Deaminase | 1 | 2016 | 5 | 0.030 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 234 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1203 | 0.030 |
Why?
| | Electroporation | 1 | 2016 | 37 | 0.030 |
Why?
| | Placebos | 1 | 2016 | 200 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 594 | 0.030 |
Why?
| | Virion | 1 | 2015 | 84 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 1997 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2014 | 10232 | 0.030 |
Why?
| | Sevelamer | 1 | 2014 | 9 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 591 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 522 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 37 | 0.030 |
Why?
| | Drug Resistance, Viral | 1 | 2014 | 110 | 0.030 |
Why?
| | Treatment Failure | 1 | 2014 | 339 | 0.030 |
Why?
| | Prospective Studies | 1 | 2004 | 7150 | 0.020 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2011 | 55 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2011 | 109 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1836 | 0.020 |
Why?
| | Diet | 1 | 2019 | 1211 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2015 | 851 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2018 | 1018 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 162 | 0.020 |
Why?
| | Stroke | 1 | 2018 | 1071 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 763 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1018 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1037 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 148 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 33 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 560 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 462 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2007 | 232 | 0.010 |
Why?
| | B7-H1 Antigen | 1 | 2007 | 198 | 0.010 |
Why?
| | Ligands | 1 | 2007 | 619 | 0.010 |
Why?
| | Selection Bias | 1 | 2005 | 37 | 0.010 |
Why?
| | Gene Products, env | 1 | 2004 | 6 | 0.010 |
Why?
| | Gene Products, pol | 1 | 2004 | 6 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 461 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 471 | 0.010 |
Why?
| | Genes, MHC Class I | 1 | 2004 | 34 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 832 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2450 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1870 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 284 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2004 | 695 | 0.010 |
Why?
| | Research Design | 1 | 2005 | 1043 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1614 | 0.010 |
Why?
| | Lung | 1 | 2005 | 3928 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|